drug
risankizumab
Marketedupdated 6mo agoby $ABBV AbbVie Inc.
Approvedannual revenue · 2024–2024peak $11.7B
community read0 votes
🐶 often sniffed alongside
top 3Antibody drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 6 investigational indications.
indications
investigational
IBD (Crohn's + UC)
all catalysts(23)
approval · 23
Apr 23, 2019
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Mar 20, 2020
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Apr 26, 2021
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Apr 26, 2021
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Jan 21, 2022
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Jun 16, 2022
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Jun 16, 2022
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Sep 23, 2022
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Sep 23, 2022
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Jan 3, 2024
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Jan 3, 2024
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Mar 4, 2024
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Mar 4, 2024
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Jun 18, 2024
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Jun 18, 2024
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
May 7, 2025
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
May 7, 2025
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Sep 3, 2025
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Sep 3, 2025
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Mar 6, 2026
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Mar 6, 2026
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Mar 18, 2026
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Mar 18, 2026
approval
$ABBV294.55-0.16%
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Trials studying risankizumab
- phase4Risankizumab for Refractory Perianal Fistulizing Crohn's Disease
- phase3A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
- phase3A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- phase3Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
- phase2Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- phase3A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
- phase3A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
- —VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
News(10)
- J&J and Protagonist’s Icotyde improves psoriatic arthritis but AbbVie’s Skyrizi likely to reignA Phase 3 trial showed that Johnson & Johnson and Protagonist Therapeutics’ oral therapy Icotyde improved psoriatic arthritis symptoms but AbbVie’s injectable is likely to hold court based on highe…biospace · 7d ago
- AbbVie bets up to $1.47B for Nxera’s discarded IBD programAbbVie’s $100 million upfront cash payment will purchase global rights to Nxera’s deprioritized oral small molecule, which has already completed Phase 1 testing.biospace · 12d ago
- AbbVie pens $1.4B deal for deprioritized IBD drug from NxeraAbbVie has added another angle to its relationship with Nxera, with the Big Pharma paying $100 million upfront for a phase 1 inflammatory bowel disease candidate.fiercebiotech · 13d ago
- AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on dealsStrong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit all-time highs.biospace · 17d ago
- Another autoimmune CAR-T death; Treasury zeroes in on China dealsA patient who received Bristol Myers’ zola-cel died 44 days later. Elsewhere, Gilead paid nearly $1.3 billion for a potential threat to J&J’s newly approved psoriasis pill.biopharma_dive · 21d ago
- As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune visionAbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster ca…biospace · 28d ago
- AbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trialAbbVie’s Skyrizi-based combination therapy for inflammatory bowel disease worked better than Skyrizi alone in a mid-stage trial in Crohn’s disease, the company said Monday. The new product is coden…endpoints · 28d ago
- AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trialAbbVie’s next-generation Crohn’s disease combination candidate has beaten Skyrizi in a midphase clinical trial.fiercebiotech · 29d ago
- Biotech builder Paragon imports Apogee's top brass after AbbVie buyoutIt’s been a busy morning for Paragon Labs. In addition to bringing over much of the leadership team from AbbVie-acquired Apogee Therapeutics, Paragon has overseen a reverse merger to take its hyper…fiercebiotech · 1mo ago
- Pharma’s $500B patent problem will come in waves — not as a cliffMerck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.biopharma_dive · 1mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that